<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00926302</url>
  </required_header>
  <id_info>
    <org_study_id>MCPE08034M1</org_study_id>
    <secondary_id>TSGHIRB097-02-006</secondary_id>
    <secondary_id>C159</secondary_id>
    <nct_id>NCT00926302</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study of Levetiracetam Versus Keppra</brief_title>
  <official_title>A Randomized, Single, Two-Way Crossover Pivotal Study to Assess the Bioequivalence Study of Levetiracetam vs. Keppra Administered Under Fasting Conditions to Healthy Adult Subject</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tri-Service General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tri-Service General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the bioequivalence of Levetiracetam versus Keppra
      administered under fasting conditions to healthy adult subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, single, two-way crossover pivotal study. The pharmacokinetic
      blood samples and vital signs were obtained before and after administration at scheduled
      intervals as indicated in the study protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the bioequivalence</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levetiracetam one period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Keppra one period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam (Lotus Pharmaceutical Co.,Ltd.)</intervention_name>
    <description>Levetiracetam 500mg/tablet Oral once</description>
    <arm_group_label>Test drug</arm_group_label>
    <other_name>The test drug Levetiracetam is no brand name.</other_name>
    <other_name>Manufacturer:Lotus Pharmaceutical Co.,Ltd.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Keppra (Levetiracetam - USB SA Pharma Sector)</intervention_name>
    <description>Levetiracetam 500mg/tablet oral once</description>
    <arm_group_label>Reference drug</arm_group_label>
    <other_name>Keppra</other_name>
    <other_name>Manufracturer:USB SA Pharma Sector</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed written informed consent before enrollment into the study, ability
             to communicate with the investigators, and to understand and comply with the
             requirements of the study.

          2. Healthy adult male, aged between 20 and 40 years old.

          3. Body Mass Index between 18.5 and 25 (inclusive).

          4. Physically and mentally healthy subjects as confirmed by an interview, medical
             history, clinical examination, chest x-ray and electrocardiogram.

          5. No significant deviation from normal biochemistry examination.

          6. No significant deviation from normal hematology examination.

          7. No significant deviation from normal urinalysis examination.

        Exclusion Criteria:

          1. History of drug or alcohol abuse within the past year.

          2. Medical history of severe drug allergy or sensitivity to analogous drug.

          3. Evidence of acute or chronic disease or having undergone surgery from 4 weeks prior to
             Period I dosing.

          4. Evidence of any clinical significant renal, cardiovascular, hepatic, hematopoietic,
             neurological, pulmonary or gastrointestinal pathology.

          5. Ongoing peptic ulcer and constipation.

          6. Planned vaccination during the time course of the study.

          7. Taking any clinical investigation drug from 2 months prior to Period I dosing.

          8. Use of any medication, including herb medicine or vitamins from 4 weeks before the
             study.

          9. Blood donation of more than 500 mL within the past 3 months.

         10. A positive Hepatitis B surface antigen or positive Hepatitis C antibody result.

         11. A positive test for HIV antibody.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>I-Shin Shiah, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tri-Service General Hospital</affiliation>
  </overall_official>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2009</study_first_submitted>
  <study_first_submitted_qc>June 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2009</study_first_posted>
  <last_update_submitted>June 22, 2009</last_update_submitted>
  <last_update_submitted_qc>June 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>I-Shin Shiah/The Head of Department of Psychiatry</name_title>
    <organization>Tri-Service General Hospital</organization>
  </responsible_party>
  <keyword>The bioequivalence of Levetiracetam vs. Keppra</keyword>
  <keyword>volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

